Soluble TWEAK plasma levels increase after renal transplantation and associate with the improvement of endothelial function

European Journal of Clinical Investigation

Volumn 43, Issue 12, 2013, Pages 1250-1257

  Yilmaz, Mahmut I ^a   Sonmez, Alper ^a   Saglam, Mutlu ^a   Yaman, Halil ^a   Unal, Hilmi Umut ^a   Gok, Mahmut ^a   Cetinkaya, Hakki ^a   Eyileten, Tayfun ^a   Oguz, Yusuf ^a   Sari, Sebahattin ^a   Yildirim, Ali Osman ^a   Vural, Abdulgaffar ^a   Carrero, Juan J ^b   Blanco Colio, Luis M ^c  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b KAROLINSKA INSTITUTE   (Sweden)

^c 28400 Madrid   (Spain)

Author keywords

ADMA; Endothelial function; Renal transplantation; sTWEAK

Indexed keywords

CYCLOSPORIN A; GLYCOPROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N(G),N(G) DIMETHYLARGININE; PREDNISOLONE; TACROLIMUS; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BRACHIAL ARTERY; CHRONIC KIDNEY DISEASE; ENDOTHELIUM CELL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VASODILATATION;

ADMA; ENDOTHELIAL FUNCTION; RENAL TRANSPLANTATION; STWEAK;

ADULT; ARGININE; BIOLOGICAL MARKERS; BRACHIAL ARTERY; C-REACTIVE PROTEIN; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; TUMOR NECROSIS FACTORS; VASCULAR DISEASES; VASODILATION;

EID: 84888044926     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12166     Document Type: Article

References (31)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32:S112-19.
2. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004;15:1983-92.
3. Passauer J, Bussemaker E, Lassig G, Gross P. Kidney transplantation improves endothelium-dependent vasodilation in patients with end-stage renal disease. Transplantation 2003;75:1907-10.
4. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T et al. Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage? Clin Transplant 2009;23:241-8.
5. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997;272:32401-10.
6. Ortiz A, Sanz AB, Muñoz-García B, Moreno JA, Sanchez-Niño MD, Martín-Ventura JL et al. Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor Rev 2009;20:251-8.
7. Blanco-Colio LM, Martín-Ventura JL, Muñoz-García B, Orbe J, Páramo JA, Michel JB et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:916-22.
8. Yilmaz MI, Carrero JJ, Ortiz A, Martín-Ventura JL, Sonmez A, Saglam M et al. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1716-23.
9. Carrero JJ, Ortiz A, Qureshi AR, Martín-Ventura JL, Bárány P, Heimbürger O et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:110-18.
10. Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, Eyileten T et al. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol 2011;6:785-92.
11. Kielstein JT, Boger RH, Bode-Boger SM, Martens-Lobenhoffer J, Lonnemann G, Frolich JC et al. Low dialysance of asymmetric dimethylarginine (ADMA): In vivo and in vitro evidence of significant protein binding. Clin Nephrol 2004;62:295-300.
12. Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006;47:42-50.
13. Tripepi G, Mattace Raso F, Sijbrands E, Seck MS, Maas R, Boger R et al. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin J Am Soc Nephrol 2011;6:1714-21.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
16. Chen BM, Xia LW, Zhao RQ. Determination of N(G), N(G)-dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997;692:467-71.
17. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-15.
18. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
19. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003;23:168-75.
20. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003;361:827-33.
21. Lu TM, Chung MY, Lin MW, Hsu CP, Lin SJ. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography. Int J Cardiol 2011;153:135-40.
22. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-17.
23. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005;16:2449-55.
24. Lu TM, Chung MY, Lin CC, Hsu CP, Lin SJ. Asymmetric dimethylarginine and clinical outcomes in chronic kidney disease. Clin J Am Soc Nephrol 2011;6:1566-72.
25. Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H, Okumura K. Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun 2002;299:488-93.
26. Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, Martin-Ventura JL et al. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler Thromb Vasc Biol 2010;30:1253-62.
27. Muñoz-García B, Martín-Ventura JL, Martínez E, Sánchez S, Hernández G, Ortega L et al. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke 2006;37:2044-53.
28. Kim SH, Kang YJ, Kim WJ, Woo DK, Lee Y, Kim DI et al. TWEAK can induce proinflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J 2004;68:396-9.
29. Munoz-Garcia B, Moreno JA, Lopez-Franco O, Sanz AB, Martin-Ventura JL, Blanco J et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 2009;29:2061-8.
30. Munoz-Garcia B, Madrigal-Matute J, Moreno JA, Martin-Ventura JL, Lopez-Franco O, Sastre C et al. TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. Cardiovasc Res 2011;89:225-33.
31. Moreno JA, Muñoz-Garcia B, Martin-Ventura JL, Madrigal-Matute J, Orbe J, Páramo JA et al. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis 2009;207:103-10.